-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2023-509846-36-00
9
2020-05-29
Advanced Solid Tumors
-
2024-516741-39-00
6
2020-01-14
Haemophilia A
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-507883-38-00
5
2019-11-18
Systemic Juvenile Idiopathic Arthritis
-
2023-507794-17-00
4
2019-11-11
Childhood Epilepsy
-
2023-507149-27-00
5
2019-11-04
Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small
-
2023-509343-27-00
11
2019-10-28
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
-
2023-503433-21-00
5
2019-10-03
Behçet’s disease is a chronic, relapsing, multisystem inflammatory dis
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-503629-20-00
9
2018-06-27
Metastatic breast cancer, including triple negative breast cancer (TNB
-
2023-504880-18-00
9
2018-04-18
Neuroblastoma (NBL)
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2022-502706-33-00
6
2018-01-10
Patients with invasive breast cancer in early stages
-
2023-504520-26-00
5
2017-10-19
Duchenne Muscular Dystrophy (DMD)
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2023-506987-15-00
9
2016-11-17
Metastatic Castration-Resistant Prostate Cancer
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2024-518254-16-00
5
2013-03-01
Acute Myeloid Leukemia (Pediatric 0-18 years)
-
2023-504610-30-01
4
2026-04-29
Acute kidney injury after cardiac surgery